Precision’s Goldman and Lakdawalla in WSJ: Look to Major League Baseball for Drug Pricing Insight
In a new commentary appearing in The Wall Street Journal, Precision Health Economics cofounders Dana Goldman and Darius Lakdawalla turn to the national pastime to provide a fresh perspective on the issue of drug pricing and the return on investment pharmaceutical companies need to sustain innovation. (more…)
Precision for Value’s Jackie DeAngelis Discusses Common Launch Mistakes
In a new commentary for PharmExec.com, Precision for Value SVP and Managing Director Jackie De Angelis outlines some of the most common mistakes that hinder access when launching a new drug. (more…)
Precision’s Rademacher Weighs In on Top 4 Approaches to Pharmaceutical Cost Reduction
In the latest edition of Managed Healthcare Executive, Precision for Value’s Kellie Rademacher provides her perspective on the magazine’s second annual managed care pharmacy survey. (more…)
Precision’s Jeremy Schafer in Clinical Leader: Initiate Value Story in Oncology Clinical Trials
In a new guest column appearing in the latest edition of Clinical Leader, Precision for Value’s Jeremy Schafer argues for the inclusion of value measurements into oncology trials, outlining the potential end points as well as the significant rewards that can be gained after product launch due to the enhanced value proposition. (more…)
Shafrin Blog Named to Top 100 Economics Blogs of 2017 List
For the second year in a row, Precision Health Economics Senior Research Economist Jason Shafrin’s blog, “Healthcare Economist,” has been named by Intelligent Economist to their list of Top 100 Economics Blogs (worldwide). (more…)